Kala Pharmaceuticals (NSDQ:KALA) today priced its initial public offering of 6 million shares of common stock at $15.00 apiece. The IPO is slated to bring in nearly $90 million for the Waltham, Mass.-based company. The offering, which is expected to close on July 25, includes a 30-day option for underwriters to buy up to 900,000 additional shares […]
Featured
Catalent, Rutgers partner to study pediatric drug formulation and delivery
The Catalent Applied Drug Delivery Institute said today that it inked a deal to work with the dept. of pharmacy practice at Rutgers University in an effort to identify and address the challenges linked to pediatric drug formulation and delivery. The collaboration plans to focus on the development and administration of medicines to children by […]
Braeburn, Camurus seek FDA nod for buprenorphine depot
Camurus AB (STO:CAMX) and Braeburn Pharmaceuticals said today that the companies submitted a new drug application to the FDA for its weekly and monthly buprenorphine depots to treat opioid use disorder. Braeburn also reported that it applied for priority review of its application, which could potentially shorten the company’s path to the market. The NDA submission was supported […]
Study: Microneedle patch, protein combo could boost efficacy of flu vaccine
Researchers at Georgia State University and Georgia Institute of Technology have devised a method to boost the efficacy of a traditional influenza vaccine. The team combined a fusion protein into a microneedle patch made from a biocompatible polymer. The patch’s needles are biodegradable, releasing vaccine into the skin as they dissolve. Mice receiving a conventional […]
Lawsuit stalls approval of Merck’s insulin injection
Merck (NYSE:MRK) said today that the FDA granted tentative approval for its Lusduna Nexvue insulin glargine injection. The biologic basal insulin met regulatory standards, the company said, but a patent infringement lawsuit initiated by competitor Sanofi (NYSE:SNY) in September of last year invoked an automatic delay for the drug-device combination product’s final approval. The stay could last […]
Akorn shareholders approve merger deal with Fresenius Kabi
Akorn Inc. (NSDQ:AKRX) shareholders voted yesterday to approve its $4.75 billion merger deal with German healthcare company Fresenius (ETR:FRE). Fresenius’ Kabi division announced in April that it inked a deal to acquire the generic drugmaker, bringing with it a portfolio of ophthalmic drugs, ear drops, nasal sprays, respiratory drugs and medical creams. Since chief executive Stephan Sturm took over […]
Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial
Mylan (NSDQ:MYL) and Theravance Biopharma, Inc. (NSDQ:TBPH) touted safety data yesterday from the late-stage trial of its once-daily inhaled bronchodilator, revefenacin, in patients with chronic obstructive pulmonary disease. If approved, revefenacin would be the first nebulized long-acting muscarinic antagonist on the market for COPD patients in the U.S. Revefenacin was generally well-tolerated among the 1,055 patients who participated in the […]
Inovio prices $75m public offering
Inovio Pharmaceuticals (NSDQ:INO) said today that it priced its underwritten public offering of 12.5 million shares of common stock at $6.00 apiece. The offering is expected to bring in nearly $75 million for the Plymouth Meeting, Penn.-based company. The offering, which is expected to close on July 25, includes a 30-day option for underwriters to buy […]
Antibiotic-eluting polymer could help treat prosthetic joint infections
Researchers from Massachusetts General Hospital have developed an antibiotic-eluting polymer that could be used to treat infections in orthopedic implants, according to a report published in Nature Biomedical Engineering. Traditionally, treating a prosthetic joint infection involves removing an implant and replacing it with a temporary spacer made from antibiotic-releasing bone cement for at least six […]
Leukemia trial to match patients with drugs based on genetic biomarkers
The Leukemia & Lymphoma Society said today that its expanding its Beat AML Master trial to include five investigational treatments for acute myeloid leukemia. The trial, which launched in October last year, has enrolled 70 patients and has garnered support by Alexion Pharmaceuticals (NSDQ:ALXN), Boehringer Ingelheim, Celgene (NSDQ:CELG) and Gilead Sciences (NSDQ:GILD), all of which are providing investigational […]